Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 496

1.

Immunohistochemical separation of follicular variant of papillary thyroid carcinoma from follicular adenoma.

Nakamura N, Erickson LA, Jin L, Kajita S, Zhang H, Qian X, Rumilla K, Lloyd RV.

Endocr Pathol. 2006 Fall;17(3):213-23.

PMID:
17308358
2.

Immunohistochemical diagnosis of papillary thyroid carcinoma.

Cheung CC, Ezzat S, Freeman JL, Rosen IB, Asa SL.

Mod Pathol. 2001 Apr;14(4):338-42.

3.
4.

Galectin-3, fibronectin-1, CITED-1, HBME1 and cytokeratin-19 immunohistochemistry is useful for the differential diagnosis of thyroid tumors.

Prasad ML, Pellegata NS, Huang Y, Nagaraja HN, de la Chapelle A, Kloos RT.

Mod Pathol. 2005 Jan;18(1):48-57.

6.

[Detection of cytokeratin 19 and thyroperoxidase expressions in the diagnosis of thyroid diseases].

Yang QX, Shao CK, Feng ZY, Huang BQ, Han AJ, Xiong M, Zhao WL, Wu TT.

Di Yi Jun Yi Da Xue Xue Bao. 2005 Jun;25(6):678-81. Chinese.

7.

[Diagnosis of the follicular variant of papillary thyroid carcinoma. Significance of immunohistochemistry].

Guyétant S, Michalak S, Valo I, Saint-André JP.

Ann Pathol. 2003 Feb;23(1):11-20. French.

PMID:
12743496
8.

Usefulness of HBME-1, cytokeratin 19 and galectin-3 immunostaining in the diagnosis of thyroid malignancy.

de Matos PS, Ferreira AP, de Oliveira Facuri F, Assumpção LV, Metze K, Ward LS.

Histopathology. 2005 Oct;47(4):391-401.

PMID:
16178894
9.

MicroRNA analysis as a potential diagnostic tool for papillary thyroid carcinoma.

Chen YT, Kitabayashi N, Zhou XK, Fahey TJ 3rd, Scognamiglio T.

Mod Pathol. 2008 Sep;21(9):1139-46. doi: 10.1038/modpathol.2008.105.

10.

Immunohistochemical analysis of thyroid follicular neoplasms and BRAF mutation correlation.

Atik E, Guray M, Gunesacar R, Ozgur T, Canda T.

Indian J Cancer. 2014 Jan-Mar;51(1):63-8. doi: 10.4103/0019-509X.134648.

11.

[Comparison of CD15, galectin-3 and HBME-1 expression in follicular thyroid neoplasms].

Bogdańska M, Górnicka B, Ziarkiewicz-Wróblewska B, Koperski L, Morton M, Wasiutyński A.

Endokrynol Pol. 2006 Jul-Aug;57(4):314-9. Polish.

PMID:
17006830
12.

Cytokeratin19 expression discriminates papillary thyroid carcinoma from other thyroid lesions and predicts its aggressive behavior.

Isic Dencic T, Cvejic D, Paunovic I, Tatic S, Havelka M, Savin S.

Med Oncol. 2013 Mar;30(1):362. doi: 10.1007/s12032-012-0362-1.

PMID:
23269585
13.

Characterization of thyroid 'follicular neoplasms' in fine-needle aspiration cytological specimens using a panel of immunohistochemical markers: a proposal for clinical application.

Saggiorato E, De Pompa R, Volante M, Cappia S, Arecco F, Dei Tos AP, Orlandi F, Papotti M.

Endocr Relat Cancer. 2005 Jun;12(2):305-17.

15.

Galectin-3 does not reliably distinguish benign from malignant thyroid neoplasms.

Mehrotra P, Okpokam A, Bouhaidar R, Johnson SJ, Wilson JA, Davies BR, Lennard TW.

Histopathology. 2004 Nov;45(5):493-500.

PMID:
15500653
16.

Immunostaining of galectin-3 and CD44v6 using fine-needle aspiration for distinguishing follicular carcinoma from adenoma.

Maruta J, Hashimoto H, Yamashita H, Yamashita H, Noguchi S.

Diagn Cytopathol. 2004 Dec;31(6):392-6.

PMID:
15540177
17.
18.

CD57 (Leu-7) expression is helpful in diagnosis of the follicular variant of papillary thyroid carcinoma.

Khan A, Baker SP, Patwardhan NA, Pullman JM.

Virchows Arch. 1998 May;432(5):427-32.

PMID:
9645441
20.

HBME-1 expression in follicular tumor of the thyroid: an investigation of whether it can be used as a marker to diagnose follicular carcinoma.

Ito Y, Yoshida H, Tomoda C, Miya A, Kobayashi K, Matsuzuka F, Kakudo K, Kuma K, Miyauchi A.

Anticancer Res. 2005 Jan-Feb;25(1A):179-82.

Items per page

Supplemental Content

Support Center